Literature DB >> 19646419

NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells.

Takashi Nishina1, Noritaka Yamaguchi, Jin Gohda, Kentaro Semba, Jun-ichiro Inoue.   

Abstract

Pancreatic cancer has one of the poorest prognoses among human neoplasms. Constitutive activation of NF-kappaB is frequently observed in pancreatic cancer cells and is involved in their malignancy. However, little is known about the molecular mechanism of this constitutive NF-kappaB activation. Here, we show that the alternative pathway is constitutively activated and NF-kappaB-inducing kinase (NIK), a mediator of the alternative pathway, is significantly expressed in pancreatic cancer cells. siRNA-mediated silencing of NIK expression followed by subcellular fractionation revealed that NIK is constitutively involved in the processing of p100 and nuclear transport of p52 and RelB in pancreatic cancer cells. In addition, NIK silencing significantly suppressed proliferation of pancreatic cancer cells. These results clearly indicate that NIK is involved in the constitutive activation of the alternative pathway and controls cell proliferation in pancreatic cancer cells. Therefore, NIK might be a novel target for the treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646419     DOI: 10.1016/j.bbrc.2009.07.125

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.

Authors:  Aaron K Holley; Yong Xu; Daret K St Clair; William H St Clair
Journal:  Ann N Y Acad Sci       Date:  2010-07       Impact factor: 5.691

Review 2.  NF-κB inducing kinase: a key regulator in the immune system and in cancer.

Authors:  Yee Mon Thu; Ann Richmond
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-03       Impact factor: 7.638

3.  GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.

Authors:  Deepali Bang; Willie Wilson; Meagan Ryan; Jen Jen Yeh; Albert S Baldwin
Journal:  Cancer Discov       Date:  2013-04-01       Impact factor: 39.397

4.  Requiem protein links RelB/p52 and the Brm-type SWI/SNF complex in a noncanonical NF-kappaB pathway.

Authors:  Toshio Tando; Aya Ishizaka; Hirotaka Watanabe; Taiji Ito; Shun Iida; Takeshi Haraguchi; Taketoshi Mizutani; Tomonori Izumi; Toshiaki Isobe; Taishin Akiyama; Jun-ichiro Inoue; Hideo Iba
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

5.  Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis.

Authors:  Chengyin Min; Yingshe Zhao; Mathilde Romagnoli; Philip C Trackman; Gail E Sonenshein; Kathrin H Kirsch
Journal:  J Cell Biochem       Date:  2010-12-01       Impact factor: 4.429

6.  Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?

Authors:  Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2013-05       Impact factor: 4.512

7.  Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells.

Authors:  Onat Kadioglu; Thomas Efferth
Journal:  Invest New Drugs       Date:  2016-03-14       Impact factor: 3.850

8.  Both canonical and non-canonical NF-κB activation contribute to the proliferative response of the middle ear mucosa during bacterial infection.

Authors:  Chang Gun Cho; Kwang Pak; Nicholas Webster; Arwa Kurabi; Allen F Ryan
Journal:  Innate Immun       Date:  2016-09-23       Impact factor: 2.680

9.  Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis.

Authors:  Tewfik Hamidi; Hana Algül; Carla Eliana Cano; Maria José Sandi; Maria Inés Molejon; Marc Riemann; Ezequiel Luis Calvo; Gwen Lomberk; Jean-Charles Dagorn; Falk Weih; Raul Urrutia; Roland Michael Schmid; Juan Lucio Iovanna
Journal:  J Clin Invest       Date:  2012-05-08       Impact factor: 14.808

10.  Molecular hallmarks of adult T cell leukemia.

Authors:  Makoto Yamagishi; Toshiki Watanabe
Journal:  Front Microbiol       Date:  2012-09-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.